Use of lrig1 as a biomarker for identifying a subject for application of anti-c-met antibodies

The present invention relates to: a biomarker for identifying a subject for the application of anti c-Met antibodies; a method of identifying the subject for the application of the anti c-Met antibodies including a step of measuring the Cbl concentration, the Cbl mutation, and/or the mutation of a Cbl combining domain of c-Met of tumour cells of the subject; and a preventing and/or treating method of c-Met related diseases including a step of injecting an effective dose of the anti c-Met antibodies to the subject.